Seeking Alpha

DelMar Pharmaceuticals, Inc. (DMPI)

  • Aug. 29, 2014, 9:39 AM
    • DelMar Pharmaceuticals (OTCQB:DMPI) six-month results: Revenues: $0; Operating Expenses: $2.7M (-27.5%); Net Loss: ($2.8M) (+80.3%); Loss Per Share: ($0.09) (+82.4%); Quick Assets: $4.8M (+15.1%); Cash Burn: ($1.8M) (+44.9%).
    • On July 21, 2014 the BOD voted to change the fiscal year end from December 31 to June 30. The reported financial results are for the transition period.
    • No financial guidance given.
    | Comment!
Visit Seeking Alpha's
DMPI vs. ETF Alternatives
Company Description
DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company with a focus on the treatment of cancer.
Sector: Healthcare
Country: Canada